- The Czech National Property Fund is proposing the direct sale of the Vykumny Ustav Antibiotik a Biottransformaci antibiotics research institute in the Czech Republic, according to the CTK news agency's Business News. VUAB, which was established in 1949, employs 530 people. The firm is best known for its product ephedrine, of which VUAB is the second largest producer in Europe, with an annual output of 150 tonnes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze